Overview

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease

Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
To determine the safety of intrathecal (IT) PD1 antibody for Intrathecal application of PD1 antibody in metastatic solid tumors with leptomeningeal disease of solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
University Hospital Tuebingen
Treatments:
Nivolumab